Abstract
Background: GM1 gangliosidosis (GM1) is an autosomal recessive disorder characterized by the deficiency of beta-galactosidase (β-gal), a ubiquitous lysosomal enzyme that catalyzes the hydrolysis of GM1 ganglioside.
Objective: The study aims to explore the application of the AAV9-coGLB1 for effective treatment in a GM1 gangliosidosis mutant mouse model.
Methods: We designed a novel adeno-associated virus 9 (AAV9) vector expressing β-gal (AAV9- coGLB1) to treat GM1 gangliosidosis. The vector, injected via the caudal vein at 4 weeks of age, drove the widespread and sustained expression of β-gal for up to 32 weeks in the Glb1G455R/G455R mutant mice (GM1 mice).
Results: The increased levels of β-gal reduced the pathological damage occurring in GM1 mice. Histological analyses showed that myelin deficits and neuron-specific pathology were reduced in the cerebral cortex region of AAV9-coGLB1-treated mice. Immunohistochemical staining showed that the accumulation of GM1 ganglioside was also reduced after gene therapy. The reduction of the storage in these regions was accompanied by a decrease in activated microglia. In addition, AAV9 treatment reversed the blockade of autophagic flux in GM1 mice.
Conclusion: These results show that AAV9-coGLB1 reduces the pathological signs of GM1 gangliosidosis in a mouse model.
Keywords: GM1 gangliosidosis, mouse model, gene therapy, AAV9, central nervous system inflammation, autophagic flux.
[http://dx.doi.org/10.1016/j.ymgme.2019.12.012] [PMID: 31937438]
[http://dx.doi.org/10.1007/s11011-020-00650-y] [PMID: 33394287]
[http://dx.doi.org/10.1074/jbc.RA119.009811] [PMID: 31481471]
[http://dx.doi.org/10.1016/j.stemcr.2020.03.012] [PMID: 32302553]
[http://dx.doi.org/10.2174/187221412799015245] [PMID: 22264214]
[http://dx.doi.org/10.3390/ijms21186881] [PMID: 32961778]
[http://dx.doi.org/10.1016/j.cell.2020.11.033] [PMID: 33306957]
[http://dx.doi.org/10.1002/glia.23663] [PMID: 31231866]
[http://dx.doi.org/10.1111/jnc.14672] [PMID: 30697734]
[http://dx.doi.org/10.1002/1873-3468.13980] [PMID: 33131047]
[http://dx.doi.org/10.1093/brain/awg089] [PMID: 12615653]
[http://dx.doi.org/10.1177/1535370221993052] [PMID: 33583210]
[http://dx.doi.org/10.1159/000509798] [PMID: 33202405]
[http://dx.doi.org/10.1186/s12974-018-1137-1] [PMID: 29665808]
[http://dx.doi.org/10.1093/hmg/ddv168] [PMID: 25964428]
[http://dx.doi.org/10.1016/j.cell.2010.01.040] [PMID: 20303873]
[http://dx.doi.org/10.1089/hum.2018.206] [PMID: 33045869]
[http://dx.doi.org/10.1016/j.bbrc.2007.12.187] [PMID: 18190792]
[http://dx.doi.org/10.1016/j.jmb.2020.02.012] [PMID: 32087199]
[http://dx.doi.org/10.1111/acel.12409] [PMID: 26486234]